Biotech News

Pfizer Inc. said Wednesday that its blockbuster vaccine against pneumonia, blood and other infections met its goal of preventing illness in vulnerable elderly patients in a huge study required by U.S. regulators.

The number of U.S. cattle deaths that may be linked to the Merck & Co Inc feed additive Zilmax are much higher than the figures reported by the drug company to the federal government, according to a research study published on Wednesday.

New York's Albany County issued a moratorium on Wednesday on the expansion of crude oil processing in the Port of Albany, pending a public health investigation.

Expensive new drugs for hepatitis C may work better than older treatments, but their high cost undermines their value, a panel of experts said Monday during a daylong forum in San Francisco Monday.

Trading of Pfizer Inc. stock was halted briefly in Wednesday trading on news that a court has invalidated a patent for one of its top-selling medicines, potentially opening the door for cheaper generic versions 18 months sooner than expected.

According to the World Health Organization, there were approximately 207 million cases of malaria worldwide in 2012, 627,000 of which proved fatal.

Giving companies like Nuclea Biotechnologies seed money to grow is exactly how Gov. Deval Patrick believes he is "intentionally" creating jobs in the life science field.

David L. Johnson is President and CEO of the Central Indiana Corporate Partnership, and was the keynote speaker at a "Cleveland Connects" forum on the region's biotechnology industry held here at ideastream.

89 percent ag... )--Inter Parfums, Inc. today reported results for the fourth quarter ended December 31, 2013.

Teva Pharmaceutical Industries Ltd agreed to pay $27.6 million to settle charges that it paid kickbacks to a Chicago psychiatrist to induce him to prescribe an anti-schizophrenia drug to patients, resulting in more than 100,000 false Medicaid and Medicare claims.

An innovative hepatitis C drug that was only recently hailed as a breakthrough treatment is facing skepticism from some health care providers, as they consider whether it is worth the $1,000-a-pill price set by manufacturer Gilead Sciences Inc. A panel of California medical experts voted Monday that Gilead's Sovaldi represents a "low value" ... (more)

US stocks were set for a flat open on Tuesday after a slight decline in the prior session left the S&P 500 within striking distance of its recent record high and amid investor caution as tensions in Ukraine continued.

When President Bill Clinton announced in 2000 that Craig Venter and Dr. Francis Collins of the National Human Genome Research Institute had succeeded in mapping the human genome, he solemnly declared that the discovery would "revolutionize" the treatment of virtually all human disease.

While superficial evidence of a bubble exists, I believe a deeper look at the issue reveals that such talk is premature.

Medical-device companies have been largely left out of the past year's parade of biotech businesses onto the public markets, yet on Monday two companies selling devices to treat the very same ailment filed their initial public offering paperwork.

La Jolla Pharmaceutical Co said its experimental drug to treat chronic kidney disease met the main goal of improving kidney function in a mid-stage study.

Conversations with clients this week revealed that many investors are also weighing mixed feelings about valuation and the potential for growth.

Discouraging economic news from China and Japan stoked investors' worries about a global slowdown, sending U.S. stocks lower Monday.

Based on the way they are betting their million-dollar-a-year jobs and the firm's capital in multi-million dollar lumps.

ZENBU, a new, freely available bioinformatics tool enables researchers to quickly and easily integrate, visualize and compare large amounts of genomic information resulting from large-scale, next-generation sequencing experiments.